HONG KONG, 26 June 2026 — Luye Pharma Group Ltd. announced that every resolution tabled at its annual general meeting (AGM) secured clear approval, underscoring broad shareholder support for the company’s governance slate and capital management flexibility.
Robust voter base: The poll covered the company’s entire issued share capital of 3.99 billion shares, with no voting restrictions or mandatory abstentions reported. Computershare Hong Kong Investor Services acted as scrutineer.
Key voting outcomes • FY2025 results adopted: The audited consolidated financial statements and accompanying reports were approved by 99.74% of votes cast (1.04 billion shares in favour).
• Board composition confirmed: – Non-executive Director Song Rui Lin re-elected with 98.44% support. – Independent non-executive directors (INEDs) Leung Man Kit, Zhang Hua Qiao and Choy Sze Chung Jojo—each serving on the board for over nine years—were returned with approval rates of 95.37%, 94.54% and 94.93%, respectively. – Director remuneration authority granted to the board with 99.40% support.
• Auditor re-appointment: Ernst & Young will continue as external auditor for the 2026 fiscal year after receiving 99.76% of votes in favour.
• Capital mandates renewed: – General issuance mandate allowing the board to allot, issue or transfer treasury shares up to 20% of issued share capital received 90.48% approval. – Share repurchase mandate of up to 10% of issued shares gained 99.76% support. – Extension of the issuance mandate by the amount of any shares repurchased passed with 90.49% backing.
Governance notes: All directors attended the meeting except Yang Rong Bing and Huang Liming, who were absent due to other work commitments. Passage of all resolutions requires a simple majority; each achieved at least 90% affirmative votes, reaffirming shareholder confidence in the board’s stewardship and capital management strategy.
Comments